EnteroBiotix
Biotechnology Research11-50 Employees
EnteroBiotix is a clinical-stage biotechnology company focused on developing microbiome-based therapies aimed at treating gastrointestinal and metabolic diseases. Its lead program, EBX-102-02, is an orally delivered, full-spectrum microbiome therapeutic intended for irritable bowel syndrome with constipation, with ongoing Phase 2 development. The company positions itself within the biotechnology and microbiome therapeutics space as its platform approach seeks to address disruptions in gut microbiome structure and function that contribute to disease, offering potential improvements in care for patients with gut-related conditions. Based in Glasgow, Scotland, the firm operates in a research-driven environment with attention to late-stage clinical data and dissemination of findings at major medical forums, such as Digestive Disease Week and EASL, indicating active engagement with the broader medical community.
1-888-653-2347 
support@leadiq.com 
